The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
AASLD guidelines for treatment of chronic hepatitis B
Open accessAbstract
Potential conflict of interest: Dr. Jonas consults and received grants from Gilead. She received grants from Bristol‐Myers Squibb and Roche. Dr. Chang advises Genentech, Alnylam, and Arbutus. Dr. Terrault consults for Bristol‐Myers Squibb and received grants from Gilead. Dr. Bzowej received grants from Gilead, Synageva, and Ocera. The funding for the development of this Practice Guideline was provided by the American Association for the Study of Liver Diseases. This Practice Guideline was approved by the AASLD on August 1, 2015. This Practice Guideline published with accompanying Reviews by Lok et al., Jonas et al., and Brown et al. See Editorial on Page 31 Objectives and Guiding Principles Guiding Principles This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the treatment of chronic hepatitis B (CHB) virus (HBV) infection in adults and children. Unlike previous AASLD practice guidelines, this guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.1 Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of this guideline will be obtained by reading the applicable portions of the systematic reviews. This guideline focuses on using antiviral therapy in chronic HBV infection and does not address other related and important issues, such as screening, prevention, and surveillance. For broader issues related to diagnosis, surveillance, and prevention as well as treatment in special populations (e.g., liver transplant recipients) that are not addressed by this guideline, the previous AASLD guideline2 and recent World Health Organization (WHO) guideline3 are excellent additional resources. Objectives Guideline developers from the AASLD formulated a list of discrete questions that physicians are faced with in daily practice. These questions were: Should adults with immune active CHB be treated with antiviral therapy to decrease liver‐related complications? Should adults with immune‐tolerant infection be treated with antiviral therapy to decrease liver‐related complications? Should antiviral therapy be discontinued in hepatitis B e antigen (HBeAg)‐positive persons who have developed HBeAg seroconversion on therapy? Should antiviral therapy be discontinued in persons with HBeAg‐negative infection with sustained HBV DNA suppression on therapy? In HBV‐monoinfected persons, does entecavir therapy, when compared to tenofovir therapy, have a different impact on renal and bone health? Is there a benefit to adding a second antiviral agent in persons with persistent low levels of viremia while being treated with either tenofovir or entecavir? Should persons with compensated cirrhosis and low levels of viremia be treated with antiviral agents? Should pregnant women who are hepatitis B surface antigen (HBsAg) positive with high viral load receive antiviral treatment in the third trimester to prevent perinatal transmission of HBV? Should children with HBeAg‐positive CHB be treated with antiviral therapy to decrease liver‐related complications? Target Audience This guideline is intended primarily for health care professionals caring for patients with CHB. Additionally, this guideline may assist policy makers in optimizing the care of individuals living with CHB. Background Burden of Disease Globally, an estimated 240 million persons have CHB with a varying prevalence geographically, highest in Africa and Asia.4 In the United States, the National Health and Nutrition Examination Survey (1999 to 2008) identified approximately 704,000 adults with CHB,5 but with adjustments for hepatitis B infection among foreign‐born persons, the upper estimate of CHB in the United States may be as high as 2.2 million.6 Globally, deaths from cirrhosis and hepatocellular carcinoma (HCC) were estimated at 310,000 and 340,000 per year, respectively.7 To reduce the morbidity and mortality of CHB in the United States and worldwide, there is a need for continued efforts to identify infected individuals through targeted screening, prevent new infections through vaccination, and monitor and treat those at risk for complications of their CHB, including surveillance for HCC.8 Natural History in Adults and Children CHB has been traditionally characterized into four phases (Table 1), reflecting the dynamic relationship between viral replication and evolution and the host immune response. These phases are of variable duration and not every person infected with CHB will evolve through all phases. Given the dynamic nature of CHB infection, serial monitoring of HBV DNA and alanine aminotransferase (ALT) levels is important to characterize the phase of infection. A single ALT and HBV DNA level are insufficient to assign phase of infection and/or need for tre
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Ott, J. J., Stevens, G. A., Groeger, J., & Wiersma, S. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.116 · Cited by 1,843
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Cited by
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Self-citationApproved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 831
Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6701a1 · Cited by 815
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Chronic Hepatitis B Infection: A Review
Tang, L. S. Y., Covert, E., Wilson, E., & Kottilil, S. (2018) · JAMA · doi:10.1001/jama.2018.3795 · Cited by 657
Buti, M., Gane, E., Seto, W. K., Chan, H. L. Y., Chuang, W.-L., Stepanova, T., Hui, A.-J., Lim, Y.-S., Mehta, R., Janssen, H. L. A., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30107-8 · Cited by 554
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Lok, A. S. F., McMahon, B. J., Brown, R. S., Wong, J. B., Ahmed, A. T., Farah, W., Almasri, J., Alahdab, F., Benkhadra, K., Mouchli, M. A., et al. (2016) · Hepatology · doi:10.1002/hep.28280 · Cited by 552
Self-citationAccelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Cooke, G. S., Andrieux-Meyer, I., Applegate, T. L., Atun, R., Burry, J. R., Cheinquer, H., Dusheiko, G., Feld, J. J., Gore, C., Griswold, M. G., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30270-x · Cited by 535
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission
Sarin, S. K., Kumar, M., Eslam, M., George, J., Al Mahtab, M., Akbar, S. M. F., Jia, J., Tian, Q., Aggarwal, R., Muljono, D. H., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30342-5 · Cited by 525
Chan, H. L. Y., Fung, S., Seto, W. K., Chuang, W.-L., Chen, C.-Y., Kim, H. J., Hui, A. J., Janssen, H. L. A., Chowdhury, A., Tsang, T. Y. O., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30024-3 · Cited by 469
HBV DNA Integration: Molecular Mechanisms and Clinical Implications
Tu, T., Budzinska, M., Shackel, N., & Urban, S. (2017) · Viruses · doi:10.3390/v9040075 · Cited by 447
Use of Liver Imaging and Biopsy in Clinical Practice
Tapper, E. B., & Lok, A. S.-F. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1610570 · Cited by 442
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Agarwal, K., Brunetto, M., Seto, W. K., Lim, Y.-S., Fung, S., Marcellin, P., Ahn, S. H., Izumi, N., Chuang, W., Bae, H., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.039 · Cited by 428
Murad, M. H. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.001 · Cited by 386
Self-citationEpidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease
Nelson, N. P., Easterbrook, P. J., & McMahon, B. J. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.06.006 · Cited by 366
Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Self-citationHepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets
Spearman, C. W., Afihene, M., Ally, R., Apica, B., Awuku, Y., Cunha, L., Dusheiko, G., Gogela, N., Kassianides, C., Kew, M., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30295-9 · Cited by 361
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.008 · Cited by 344
Brown, R. S., McMahon, B. J., Lok, A. S. F., Wong, J. B., Ahmed, A. T., Mouchli, M. A., Wang, Z., Prokop, L. J., Murad, M. H., & Mohammed, K. (2016) · Hepatology · doi:10.1002/hep.28302 · Cited by 324
Self-citationYip, T. C.-F., Wong, G. L.-H., Chan, H. L.-Y., Tse, Y.-K., Lam, K. L.-Y., Lui, G. C.-Y., & Wong, V. W.-S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.014 · Cited by 318
Limitations of non-invasive tests for assessment of liver fibrosis
Patel, K., & Sebastiani, G. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100067 · Cited by 317
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Hepatology · doi:10.1002/hep.29323 · Cited by 303
Papatheodoridis, G. V., Idilman, R., Dalekos, G. N., Buti, M., Chi, H., van Boemmel, F., Calleja, J. L., Sypsa, V., Goulis, J., Manolakopoulos, S., et al. (2017) · Hepatology · doi:10.1002/hep.29320 · Cited by 301
Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B
Jourdain, G., Ngo-Giang-Huong, N., Harrison, L., Decker, L., Khamduang, W., Tierney, C., Salvadori, N., Cressey, T. R., Sirirungsi, W., Achalapong, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708131 · Cited by 285
The Commensal Microbiota and Viral Infection: A Comprehensive Review
Li, N., Ma, W.-T., Pang, M., Fan, Q.-L., & Hua, J.-L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01551 · Cited by 283
Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions
Kennedy, P., Wagner, M., Castéra, L., Hong, C. W., Johnson, C. L., Sirlin, C. B., & Taouli, B. (2018) · Radiology · doi:10.1148/radiol.2018170601 · Cited by 271
Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023
Conners, E. E., Panagiotakopoulos, L., Hofmeister, M. G., Spradling, P. R., Hagan, L. M., Harris, A. M., Rogers-Brown, J. S., Wester, C., Nelson, N. P., Contributors, et al. (2023) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7201a1 · Cited by 268
Kim, J. H., Kim, Y. D., Lee, M., Jun, B. G., Kim, T. S., Suk, K. T., Kang, S. H., Kim, M. Y., Cheon, G. J., Kim, D. J., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.07.018 · Cited by 264
Singh, S., Muir, A. J., Dieterich, D. T., & Falck-Ytter, Y. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.016 · Cited by 263
Kim, G.-A., Lim, Y.-S., Han, S., Choi, J., Shim, J. H., Kim, K. M., Lee, H. C., & Lee, Y. S. (2018) · Gut · doi:10.1136/gutjnl-2017-314904 · Cited by 258
Murillo Perez, C. F., Harms, M. H., Lindor, K. D., van Buuren, H. R., Hirschfield, G. M., Corpechot, C., van der Meer, A. J., Feld, J. J., Gulamhusein, A., Lammers, W. J., et al. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000557 · Cited by 188
Bahrami, M., Cheraghpour, M., Jafarirad, S., Alavinejad, P., Asadi, F., Hekmatdoost, A., Mohammadi, M., & Yari, Z. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102452 · Cited by 60
Pham, T. T. H., Maria, N., Cheng, V., Nguyen, B., Toy, M., Hutton, D., Conners, E. E., Nelson, N. P., Salomon, J. A., & So, S. (2023) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2023.01.041 · Cited by 31
Jang, T.-Y., Ho, C.-C., Wu, C.-D., Dai, C.-Y., & Chen, P.-C. (2023) · Medicine · doi:10.1097/md.0000000000034276 · Cited by 10
Metadata
- Authors
- Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H.
- Venue
- Hepatology
- Published
- 2015-11-13
- Volume
- 63
- Issue
- 1
- Pages
- 261-283
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2173698250
- Cited by
- 2,006
- References
- 99
- FWCI
- 177.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.